Novel Targeted PEG Nanoparticles For Cancer Treatment And Monitoring
Funder
National Health and Medical Research Council
Funding Amount
$606,979.00
Summary
We will develop novel targeted cancer therapies based on next generation nanoparticles. These particles will deliver highly potent drugs to tumours with less adverse effects to healthy organs. The ability to image the therapeutic can be used to detect diseases at early, potentially curable stages, identify patients likely to respond to certain treatments, and predict response to therapy. Our project has the potential to increase the survival of patients suffering from the most deadly cancer.
Investigating The Therapeutic Potential Of FTY720 For Human African Trypanosomiasis
Funder
National Health and Medical Research Council
Funding Amount
$653,736.00
Summary
FTY720, is a drug currently used to treat multiple sclerosis, which we have shown is also be able to kill the parasite responsible for African sleeping sickness, Trypanosomes. We aim to identify the target the drug acts on in the parasite to have its affect. Our objective is to improve the activity further by chemical modification to produce a potent, orally available and well characterised, non-toxic drug suitable for preclinical development.
A Pharmacological Targeting Approach Implementing Albumin As A Carrier Of A Novel Chemotherapeutic
Funder
National Health and Medical Research Council
Funding Amount
$560,659.00
Summary
New drugs for cancer therapy are essential to develop that overcome resistance to standard chemotherapeutics. We have developed potent anti-cancer chelators that bind to the abundant plasma protein, albumin. Our studies showed increased tumour cell uptake of the chelator, Dp44mT, mediated by albumin. We will elucidate the mechanisms of their albumin-mediated uptake, with the aim to implement albumin nanoparticles as carriers of novel chelators to selectively target tumours.
The Bioactivity And Binding Partners Of Irukandji And Box Jellyfish Venom
Funder
National Health and Medical Research Council
Funding Amount
$596,950.00
Summary
Venom from the Box Jellyfish and Irukandji jellyfish are considered the most leathal known to science yet precious little is known on the nature of these secretions or how they harm humans. This study aims to fully characterise bioactive proteins in jellyfish venom and attempt to block their activity using regulatory-approved and experimental drugs.
A Multi-site Study Of Tamoxifen Dose Escalation Study In Breast Cancer Patients With CYP2D6 Polymorphisms (TADE Study)
Funder
National Health and Medical Research Council
Funding Amount
$340,768.00
Summary
Tamoxifen is a selective anti-oestrogenic medication commonly used to treat breast cancer. Recent evidence suggests that tamoxifen may not be adequately activated in the body of some people because of their genetic make-up, and that this may reduce its effectiveness. In this study of 120 women, we will determine whether increasing tamoxifen dosage is a useful strategy in people with low activation levels. This could provide practical guidance for patients and clinicians managing breast cancer.
Optimisation Of The Safety And Efficacy Of Protein Kinase Inhibitors Using Endogenous And Dietary Biomarkers
Funder
National Health and Medical Research Council
Funding Amount
$384,360.00
Summary
Many new cancer medicines are part of the 'kinase inhibitor' group of drugs. Although these drugs are effective in treating a range of different cancers, opportunities remain to improve the effectiveness and safety by more intelligently deciding the dose of the drug that a specific individual should receive. The research aims to assess whether the levels of chemicals normally present in the blood of individuals being treated can be used to guide the best dose an individual should receive.
Colorectal cancer (CRC) is one of the most common causes of cancer-associated death in the world. We aim to understand why some CRC patients stop responding to EGFR therapy. In particular, we will study small molecules called cytokines that are produced by the tumour microenvironment and determine if the inhibition of these cytokines can over-come the acquired resistance to therapy. Our goal is to identify new ways to improve the current treatment options for CRC patients.
Validating The NLRP3 Inflammasome As A Therapeutic Target In Motor Neuron Disease
Funder
National Health and Medical Research Council
Funding Amount
$780,249.00
Summary
There is no effective treatment for Motor Neuron Disease (MND). Two Australian’s die each day from MND, and 2 more are diagnosed. Modification of the immune system is one potential means of slowing MND. Our research team has identified a component of the immune system, which may be an ideal therapeutic target to treat this disease. Our project will test this therapeutic target in animal models of MND, and in human MND blood samples.
Immuno-polymeric Drugs For Prostate Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$626,995.00
Summary
Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.
Non-invasive Near-infrared Optical Imaging Of Neurodegeneration
Funder
National Health and Medical Research Council
Funding Amount
$312,033.00
Summary
Dementia currently affects over 240,000 Australians with an increasing health cost. A common cause of dementia occurs when proteins in the brain form deposits and brain cells degenerate and die. This project will develop a novel medical imaging method that will facilitate the detection of dying brain cells. This will enable a better understanding of the causes of cell death and the opportunity to identify the best time for meaningful therapeutic intervention.